Published in J Biol Chem on September 10, 1978
Structure and function of factor XI. Blood (2010) 1.37
Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XII. J Clin Invest (1979) 1.04
Coagulation procofactor activation by factor XIa. J Thromb Haemost (2010) 1.04
Characterization of Novel Forms of Coagulation Factor XIa: independence of factor XIa subunits in factor IX activation. J Biol Chem (2008) 1.02
Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates. J Thromb Haemost (2013) 0.99
Fibrinogen blocks the autoactivation and thrombin-mediated activation of factor XI on dextran sulfate. Proc Natl Acad Sci U S A (1992) 0.96
Coagulation factors IX and X enhance binding and infection of adenovirus types 5 and 31 in human epithelial cells. J Virol (2009) 0.95
Exosite-mediated substrate recognition of factor IX by factor XIa. The factor XIa heavy chain is required for initial recognition of factor IX. J Biol Chem (2005) 0.95
Kinetics of the Factor XIa catalyzed activation of human blood coagulation Factor IX. J Clin Invest (1984) 0.89
Mechanisms and specificity of factor XIa and trypsin inhibition by protease nexin 2 and basic pancreatic trypsin inhibitor. J Biochem (2010) 0.87
First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa. Proc Natl Acad Sci U S A (1994) 0.83
Cleavage and inactivation of Factor IX by granulocyte elastase. J Clin Invest (1983) 0.80
Coagulation factor IX mediates serotype-specific binding of species A adenoviruses to host cells. J Virol (2011) 0.77
Expression of plant sweet protein brazzein in the milk of transgenic mice. PLoS One (2013) 0.75
Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V. N Engl J Med (1994) 4.00
Deficiency of protein C in congenital thrombotic disease. J Clin Invest (1981) 3.56
Protein synthesis by native chemical ligation: expanded scope by using straightforward methodology. Proc Natl Acad Sci U S A (1999) 2.87
Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A (1977) 2.79
Behavioral and neuroendocrine characteristics of the night-eating syndrome. JAMA (1999) 2.71
Oral contraceptives and the risk of venous thrombosis. N Engl J Med (2001) 2.57
Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol (1999) 2.56
High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med (2000) 2.39
Immunological characterization of purified anti-haemophilic factor A (factor VIII) which corrects abnormal platelet retention in Von Willebrand's disease. Nat New Biol (1972) 2.30
A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A (1997) 2.22
Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost (1983) 1.96
Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem (1977) 1.86
Plasma protein S deficiency in familial thrombotic disease. Blood (1984) 1.82
Human high molecular weight kininogen. Studies of structure-function relationships and of proteolysis of the molecule occurring during contact activation of plasma. J Biol Chem (1979) 1.72
American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med (2001) 1.70
Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation (2001) 1.67
Active release of human platelet factor VIII-related antigen by adenosine diphosphate, collagen, and thrombin. J Clin Invest (1978) 1.66
Blood borne tissue factor revisited. Thromb Res (2007) 1.65
Synthesis of intrinsic factor X activator. Inhibition of the function of formed activator by antibodies to factor VIII and to factor IX. Biochemistry (1970) 1.62
Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease. J Clin Invest (1980) 1.61
Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci U S A (1976) 1.59
Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood (1982) 1.58
The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen. J Clin Invest (1977) 1.55
Activation of rabbit Hageman factor by homogenates of cultured rabbit endothelial cells. J Clin Invest (1980) 1.53
Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet (1983) 1.53
Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood (1984) 1.52
Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein. Proc Natl Acad Sci U S A (1977) 1.52
Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation (1990) 1.52
Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost (2003) 1.52
Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem (1993) 1.51
The production and availability of tissue thromboplastin in cellular populations of whole blood exposed to various concentrations of endotoxin. An assay for detection of endotoxin. Scand J Haematol (1982) 1.51
Factor V activity of platelets: evidence for an activated factor V molecule and for a platelet activator. Blood (1977) 1.50
Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood (1995) 1.50
Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost (2000) 1.49
Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates. Circulation (1991) 1.47
Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood (2001) 1.46
Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc Natl Acad Sci U S A (1978) 1.46
Human leukocyte elastase and cathepsin G inactivate factor VII by limited proteolysis. Thromb Haemost (1993) 1.45
Resistance to activated protein C is reduced in women using oral contraceptives. Blood Coagul Fibrinolysis (1994) 1.45
Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy. Eur Heart J (2002) 1.43
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost (2000) 1.43
Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med (2000) 1.40
C4b-binding protein inhibits the factor V-dependent but not the factor V-independent cofactor activity of protein S in the activated protein C-mediated inactivation of factor VIIIa. Thromb Haemost (2001) 1.40
Impairments of the protein C system and fibrinolysis in infection-associated stroke. Stroke (1996) 1.38
The biochemistry and pathophysiology of the contact system of plasma. Adv Immunol (1982) 1.34
Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI. Blood (1981) 1.34
Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost (2000) 1.32
Human factor XII (Hageman factor). Methods Enzymol (1976) 1.31
Protein C, an antithrombotic protein, is reduced in hospitalized patients with intravascular coagulation. Blood (1982) 1.30
Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate. J Lab Clin Med (1978) 1.30
Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood (1991) 1.28
Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem (1994) 1.27
Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci U S A (1985) 1.27
Inactivation of kallikrein in human plasma. J Clin Invest (1983) 1.27
Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J Exp Med (1978) 1.26
Factor VIII, a series of homologous oligomers and a complex of two proteins. Thromb Res (1974) 1.26
Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost (2001) 1.26
Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci U S A (1994) 1.25
Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest (1997) 1.23
Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet (1994) 1.23
Chorea in systemic lupus erythematosus and "lupus-like" disease: association with antiphospholipid antibodies. Semin Arthritis Rheum (1987) 1.21
Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest (1998) 1.21
Hemophilia B: characterization of genetic variants and detection of carriers. Blood (1977) 1.20
The inflammatory properties of contained and noncontained lumbar disc herniation. Spine (Phila Pa 1976) (1997) 1.19
Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest (1993) 1.17
The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost (1988) 1.17
Direct detection of activated protein C in blood from human subjects. Blood (1992) 1.17
Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood (1994) 1.16
The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood (1995) 1.16
Alteration of fibrin network by activated protein C. Blood (1994) 1.16
Formation of intrinsic factor-X activator activity, with special reference to the role of thrombin. Br J Haematol (1971) 1.16
The effect of short-term cold exposure on risk factors for cardiovascular disease. Thromb Res (1999) 1.15
Discordant effects of prednisone on anticardiolipin antibodies and the lupus anticoagulant. Arthritis Rheum (1986) 1.15
Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood (1986) 1.15
Meningococcal septicaemia treated with combined plasmapheresis and leucapheresis or with blood exchange. Br Med J (Clin Res Ed) (1984) 1.14
Quantitation of endotoxin in blood from patients with meningococcal disease using a limulus lysate test in combination with chromogenic substrate. Infection (1983) 1.13
Protein C supports platelet binding and activation under flow: role of glycoprotein Ib and apolipoprotein E receptor 2. J Thromb Haemost (2008) 1.13
Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease. Ann Rheum Dis (2004) 1.13
Purification and some characteristics of the coagulation factor IX from human plasma. Biochem J (1975) 1.12
Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology (2001) 1.11
Physiologic inhibition of human activated protein C by alpha 1-antitrypsin. J Biol Chem (1988) 1.11
Purification and characterization of plasma protein C inhibitor. Thromb Res (1989) 1.10
Activation of purified human plasma prekallikrein triggered by cell wall fractions of Escherichia coli and Staphylococcus aureus. J Infect Dis (1983) 1.10
Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. J Thromb Haemost (2006) 1.10
Sulfatide-dependent autoactivation of human blood coagulation Factor XII (Hageman Factor). J Biol Chem (1983) 1.09
Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood (1995) 1.09
Clinical studies of protein C. Semin Thromb Hemost (1984) 1.09
Total chemical synthesis of enzymatically active human type II secretory phospholipase A2. Proc Natl Acad Sci U S A (1997) 1.08
Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. Biochemistry (1980) 1.08
Inhibition of activated protein C by recombinant alpha 1-antitrypsin variants with substitution of arginine or leucine for methionine358. J Biol Chem (1990) 1.08
Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood (1989) 1.08
Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis (1985) 1.07
Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet (1999) 1.07
Activated factor VII: presence in factor IX concentrates and persistence in the circulation after infusion. Blood (1979) 1.07
Macrophages produce blood coagulation factors. FEBS Lett (1980) 1.07